[Current antimicrobial treatment of brucellosis].
D000617:Aminoglycosides / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002006:Brucellosis / Q000150:complications / Q000188:drug therapy*; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D012008:Recurrence; D012293:Rifampin / Q000627:therapeutic use; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013754:Tetracyclines / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D013754:Tetracyclines; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole; D012293:Rifampin
Tratamiento antimicrobiano actual de la brucelosis.